BEIJING: China has made marked progress in developing different types of Covid-19 vaccines, including two nucleic acid vaccines soon to enter late-stage clinical trials overseas, a senior health official said.
Zheng Zhongwei, head of China’s Covid-19 vaccine development task force, yesterday said all five vaccine development technologies pursued by Chinese researchers have seen at least one product entering human trials.
Among them, one mRNA vaccine and one DNA vaccine – both belong to the category of nucleic acid vaccine products – have each obtained approval to launch third-stage clinical trials overseas, he said.
Three domestic inactivated vaccines have gained conditional market approval and two have been granted emergency use authorisation, he said.
One recombinant sub-unit vaccine has been approved for emergency use, while three others are undergoing third-stage clinical trials and five others are going through early-stage trials.
One adenovirus-based viral vector vaccine has obtained conditional approval, and three other products have entered initial trial stages.
One viral vector vaccine based on weakened flu virus is going through second-stage clinical trials, and is preparing for third-stage trials overseas.
Meanwhile, the National Health Commission said yesterday that more than 2.11 billion doses of Covid-19 vaccines have been administered in China as of Monday.
About 970 million people nationwide have finished the vaccination process as of Monday, 77.6% of the nation’s total population, according to the commission.
“The vaccination work for the group aged between 12 to 17 years old also is going well so far,” said Wu Liangyou, deputy director of the commission’s Disease Prevention and Control Bureau.
He said the commission will continue the vaccination campaign by improving communication and promotion work with the people.
“We will make efforts to arrange time periods and places for vaccination to be easier and enhance healthcare support to secure the safety of the vaccinated,” he said.
“More promotion is needed to let people take vaccines proactively.” — China Daily/ANN